A meta-analysis comparing confocal microscopy and dermoscopy in diagnostic accuracy of lentigo maligna.

PURPOSE: We aimed to summarize the sensitivity and specificity between RCM and dermoscopy in LM diagnosis. METHODS: A meta-analysis was conducted to the study. PubMed, Google Scholar, Cochrane Library, and Wiley Online Library database were searched for relevant studies. The basic information of the patients, sensitivity, and specificity were calculated. I2 was used for the assessment of the heterogeneity. A random-effect model was used for analyzing the data of the literature study. RESULTS: A total of 498 patients from 7 articles were included in the study. The articles summarized the sensitivity and specificity between RCM and dermoscopy in the treatment of lentigo maligna. The overall sensitivity of RCM was 0.93, and the overall specificity was 0.89. RCM diagnostic odds ratio (DOR) was 104.38, RCM positive likelihood (+LR/PLR) was 8.50, and the negative LR (-LR/NLR) was 0.08. The overall sensitivity of dermoscopy was 0.73 (95% CI: 0.58-0.84), and the overall specificity was 0.84 (95% CI: 0.71-0.92). The DOR, +LR, and -LR of dermoscopy were 14.48, 4.65, and 0.32, respectively. CONCLUSION: RCM has a better accuracy than dermoscopy in the diagnosis of LM.

Versatile and Switchable Responsive Properties of a Lanthanide-Viologen Metal-Organic Framework.

Metal-organic frameworks (MOFs) provide intriguing platforms for the design of responsive materials. It is challenging to mobilize as many components as possible of a MOF to collaboratively accomplish multiple responsive properties. Here, reversible photochromism, piezochromism, hydrochromism, ionochromism, and luminescence modulation of an ionic Eu(III) MOF is reported furnished by cationic electron-deficient viologen units and exchangeable guest anions. Mechanistically, the extraordinarily versatile responsive properties are owed to electron transfer (ET), charge transfer (CT), and energy transfer, involving viologen as electron acceptor, anion as electron donor, luminescing Eu(III) as energy donor, and anion-viologen CT complex or ET-generated radical as energy acceptor (luminescence quencher). Moreover, guest anions and waters provide flexible handles to control the ET-based responsive properties. Water release/reuptake or exchange with organic solvents can switch on/off the response to light, while reversible anion exchange can disenable or awaken the responses to pressure, light, and water release/reuptake. The impacts of water and anions on ET are justified by the high polarity and hydrogen-bonding capability of water, the different electron donor strength of anions, and the strong I- -viologen CT interactions. The rich responsive behaviors have great implications for applications such as pressure sensors, iodide detection, and chemical logic gates.

Safety and efficacy of etanercept monotherapy for moderate-to-severe plaque psoriasis: A prospective 12-week follow-up study.

Etanercept has been shown to be effective for the treatment of moderate-to-severe plaque psoriasis. Since most clinical trials examined etanercept in combination with other drugs, the efficacy and safety of etanercept monotherapy for moderate-to-severe plaque psoriasis have not been well established. This prospective study enrolled 61 Chinese patients with moderate-to-severe plaque psoriasis to explore the efficacy and safety of etanercept monotherapy. These patients were treated with etanercept at a subcutaneous dose of 25 mg, twice a week, for 12 weeks. All the 61 patients completed the treatment and showed significant improvement in psoriasis area and severity index (PASI) scores. At 4, 8, and 12 weeks after treatment, the response rates (PASI75) were 0%, 21.31%, and 40.98%, respectively. It was concluded that etanercept monotherapy is efficacious and safe for patients with moderate- to-severe plaque psoriasis.

Safety and Efficacy of Etanercept Monotherapy for Moderate-to-severe Plaque Psoriasis: A Prospective 12-week Follow-up Study / 华中科技大学学报（医学）（英德文版）

Etanercept has been shown to be effective for the treatment of moderate-to-severe plaque psoriasis.Since most clinical trials examined etanercept in combination with other drugs,the efficacy and safety of etanercept monotherapy for moderate-to-severe plaque psoriasis have not been well established.This prospective study enrolled 61 Chinese patients with moderate-to-severe plaque psoriasis to explore the efficacy and safety of etanercept monotherapy.These patients were treated with etanercept at a subcutaneous dose of 25 mg,twice a week,for 12 weeks.All the 61 patients completed the treatment and showed significant improvement in psoriasis area and severity index (PASI) scores.At 4,8,and 12 weeks after treatment,the response rates (PASI75) were 0％,21.31％,and 40.98％,respectively.It was concluded that etanercept monotherapy is efficacious and safe for patients with moderate-to-severe plaque psoriasis.